Contact
Get in touch
For study proposals, collaboration discussions, and general inquiries — please reach out to the AsPEN Chair and the Academic & Education office.
Chair · Academic & Education office
Inquiries are routed to the AsPEN Chair (Ju-Young Shin, SKKU · SNU) and the Academic & Education office (Daniel Tsai, NCKU; Edward Lai, NCKU). Please include your name, affiliation, and a brief note of what you'd like to discuss — a study idea, a potential collaboration, joining the network, or any other question.
Propose a study to AsPEN
How a multi-country pharmacoepidemiology study takes shape through AsPEN.
AsPEN provides one coordinated channel across 20+ population-level databases in Asia-Pacific and partner sites in the UK, US, and Europe. The network's standing methodological expertise covers signal-detection, drug utilisation, and effectiveness or safety comparison.
What fits well
- Drug-utilisation comparisons across health systems
- Multi-country drug-safety signal assessment
- Cross-national validation studies in different healthcare settings
- Pregnancy / paediatric / older-adult / other vulnerable population safety where Asian databases are under-represented
- Distributed network (common data model)
- Regulatory or policy questions where cross-jurisdiction evidence supports decision-making
The proposal process
- 1
Pre-discussion
1–3 wks
Send a 2–3 sentence question by email; the Academic & Education office identifies relevant national leads.
- 2
Concept note
2–4 wks
1–2 page concept (question, population, exposure, outcome, candidate sites, lead author) submitted by email.
- 3
Network review
1–3 mo
Concept circulated at the next SIG teleconference or ISPE Asian / ICPE meeting; interested sites signal willingness.
- 4
Protocol drafting
3–6 mo
Participating sites finalise common data definitions, statistical analysis plan, and feasibility checks.
- 5
Local IRB & analysis
6–12 mo
Each site obtains IRB approval, executes locally, and returns site-level estimates.
- 6
Meta-analysis & publication
3–6 mo
Site-level results pooled centrally; manuscript drafted under AsPEN multi-site authorship conventions.
Concept to publication typically runs 18–30 months; site recruitment and IRB approval are the most variable steps.
What you bring
- A clearly-scoped research question and draft analysis plan.
- Willingness to lead protocol drafting and meta-analysis.
- Database access at your home institution (see FAQ for who this applies to).
- ISPE membership if formally joining the SIG.
What AsPEN provides
- Site recruitment across the network — one channel, many databases.
- Methodological consultation across the toolkit listed below.
- Protocol review at SIG meetings and ICPE.
- Multi-site authorship and publication coordination.
Methods we apply
AsPEN studies draw on a broad design and analytic toolkit chosen to fit the question, the available data, and the multi-country setting.
- Study design
- Active Comparator / New User · Target Trial Emulation · Sequential Trial Emulation
- Quasi-experimental
- Regression Discontinuity Design (RDD) · Difference-in-Differences (DID) · Instrumental Variable (IV) · Trend-in-Trend (TIT) · Proximal Causal Inference
- Self-controlled / signal detection
- Prescription Sequence Symmetry Analysis (PSSA) · Self-Controlled Case Series (SCCS)
- Confounding control
- Propensity Score Matching / IPTW · Clone-Censor-Weight (CCW) · Machine-learning–based confounding adjustment (Causal Forest, TMLE, Doubly Robust)
- Trajectory & data infrastructure
- Group-based trajectory modeling · Common Data Models (CDM)
FAQ
+ Do I need to be an ISPE member to propose?
No. Informal pre-discussion is open to anyone. To formally join the SIG and present proposals at SIG meetings, ISPE membership (including student rates) is required.
+ Do I need my own database access?
For academic investigators, yes — access to a database at your home institution lets us assess feasibility and study design realistically up-front. For industry partners, regulators, and clinicians without database access, this is not required; AsPEN sites can host the analysis on your behalf.
+ Is there any cost?
AsPEN does not charge for participation. Site-level costs are limited to data access (which varies by database) and the human resources required to execute the local analysis.
+ What if my study is industry-funded?
Very welcome. Discussion is coordinated through the AsPEN Academic & Education office — please outline the research question, the analytical scope, and the AsPEN sites you would like to involve.
+ Can I propose a methods-only study?
Yes — methodological work is a long-standing AsPEN strand. See the Methods we apply section above for the design and analytic toolkit currently in use across the network.
Other ways to reach us
For network membership and updates from individual labs.
Joining the SIG
Network membership is coordinated through the ISPE Community platform. Visit the AsPEN SIG page on pharmacoepi.org to request access.
Browse what we publish
See AsPEN's publication portfolio by research theme or the full chronological list.
Follow our partner labs
Click any card to open the LinkedIn page and see the latest posts.
PHDc, NCKU
Population Health Data Center, National Cheng Kung University
Tainan, Taiwan
Pharmacoepidemiology Lab, SKKU
Pharmacoepidemiology Laboratory, Sungkyunkwan University
Suwon, South Korea
CSMPR, HKU
Centre for Safe Medication Practice and Research, The University of Hong Kong
Hong Kong